Savara, Inc. (SVRA)
4.83
+0.45
(+10.27%)
USD |
NASDAQ |
Nov 06, 16:00
4.85
+0.02
(+0.41%)
After-Hours: 20:00
Savara Cash from Investing (Quarterly) : 32.60M for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 32.60M |
| March 31, 2026 | 38.78M |
| December 31, 2025 | -93.56M |
| September 30, 2025 | 21.47M |
| June 30, 2025 | 24.33M |
| March 31, 2025 | 29.33M |
| December 31, 2024 | 17.90M |
| September 30, 2024 | -98.17M |
| June 30, 2024 | 29.54M |
| March 31, 2024 | 10.79M |
| December 31, 2023 | 6.571M |
| September 30, 2023 | -56.59M |
| June 30, 2023 | -1.006M |
| March 31, 2023 | -6.095M |
| December 31, 2022 | -59.21M |
| September 30, 2022 | 33.00M |
| June 30, 2022 | 25.20M |
| March 31, 2022 | 53.66M |
| December 31, 2021 | -1.268M |
| September 30, 2021 | 12.98M |
| June 30, 2021 | -3.432M |
| March 31, 2021 | -77.74M |
| December 31, 2020 | -0.381M |
| September 30, 2020 | -6.861M |
| June 30, 2020 | 18.08M |
| Date | Value |
|---|---|
| March 31, 2020 | -1.785M |
| December 31, 2019 | 16.75M |
| September 30, 2019 | 6.59M |
| June 30, 2019 | -14.92M |
| March 31, 2019 | 7.32M |
| December 31, 2018 | 0.869M |
| September 30, 2018 | -35.71M |
| June 30, 2018 | 11.83M |
| March 31, 2018 | 9.39M |
| December 31, 2017 | -39.05M |
| September 30, 2017 | -33.44M |
| June 30, 2017 | 3.441M |
| March 31, 2017 | -0.059M |
| December 31, 2016 | 0.00 |
| September 30, 2016 | -0.003M |
| June 30, 2016 | -4.383M |
| March 31, 2016 | 4.378M |
| December 31, 2015 | -0.296M |
| September 30, 2015 | 4.431M |
| June 30, 2015 | -0.221M |
| March 31, 2015 | -0.519M |
| December 31, 2014 | -4.401M |
| September 30, 2014 | 2.812M |
| June 30, 2014 | -0.3919M |
| March 31, 2014 | 2.462M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | -- |
| Alnylam Pharmaceuticals, Inc. | -311.74M |
| Anika Therapeutics, Inc. | -1.28M |
| Vericel Corp. | -2.82M |
| Biogen, Inc. | -222.10M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -29.75M |
| Cash from Financing (Quarterly) | 0.189M |
| Free Cash Flow | -110.66M |
| Free Cash Flow Per Share (Quarterly) | -0.1182 |
| Free Cash Flow to Equity (Quarterly) | -30.26M |
| Free Cash Flow to Firm (Quarterly) | -29.97M |
| Free Cash Flow Yield | -9.51% |